Publicaciones en colaboración con investigadores/as de Universidad de Salamanca (21)

2023

  1. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  2. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  3. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model

    Molecular Oncology, Vol. 16, Núm. 19, pp. 3533-3553

  2. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  3. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2019

  1. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

    Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

  2. Cancertool: A visualization and representation interface to exploit cancer datasets

    Cancer Research, Vol. 78, Núm. 21, pp. 6320-6328

  3. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2016

  1. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases

    Science Translational Medicine, Vol. 8, Núm. 370

  2. Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis

    Journal of Pathology, Vol. 239, Núm. 4, pp. 438-449

2014

  1. A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer

    Oncogene, Vol. 33, Núm. 43, pp. 5090-5099

  2. MiRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization

    Molecular Oncology, Vol. 8, Núm. 3, pp. 689-703

  3. RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner

    Molecular Oncology, Vol. 8, Núm. 2, pp. 196-206

2012

  1. Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival

    Cancer Biomarkers, Vol. 10, Núm. 1, pp. 35-41

  2. Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma

    American Journal of Respiratory and Critical Care Medicine, Vol. 186, Núm. 1, pp. 96-105

2009

  1. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis

    Clinical Cancer Research, Vol. 15, Núm. 16, pp. 5082-5091

2008

  1. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism

    Cancer Research, Vol. 68, Núm. 7, pp. 2275-2285

2007

  1. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model

    Journal of Molecular Medicine, Vol. 85, Núm. 9, pp. 1015-1029